Prostate cancer is personal. Your care should be, too.
Every man who hears the words “you have prostate cancer” begins a different journey. For some, the question is whether to treat or safely watch. For others, whether the cancer has returned. For many, how to make sense of PSA results, scans, biopsies, genetics, and the uncertainty that comes with every next step.
Oncovera exists to make that journey clearer — combining advanced science, intelligent technology, and compassionate support to help patients, families, and physicians understand what is happening, what matters, and what may come next.
Precision insight · Human guidance · Prostate cancer care made clearer
Investigating new ways to treat the prostate cancers that won't wait.
Most prostate cancers grow slowly. But a meaningful subset are aggressive from the start — or become aggressive over time, resisting hormone therapy and spreading beyond the prostate. These are the cancers that take lives, and the ones today's tools struggle most to detect, treat, and track.
Oncovera is built to focus here: on the biology behind aggressive prostate cancer, and on what it takes to change its trajectory.
Reading the full biology of a cancer, not just one number.
"Omics" is a family of technologies that look at cancer at many layers at once — instead of relying on a single test or scan.
- Genomics — the DNA changes that drive the cancer.
- Transcriptomics — which genes the cancer is actively turning on or off.
- Proteomics — the proteins the cancer is actually making and using.
- Metabolomics — the chemical fuel the cancer runs on.
- Liquid biopsy & ctDNA — cancer signals captured from a simple blood draw, over time.
Together, these layers describe a cancer's identity, behavior, and weaknesses with a depth that a PSA value or a single biopsy slide simply cannot reach.
Turning massive, messy biology into insights a clinician can use.
Omics produces enormous amounts of data. AI is what makes it usable — finding patterns across thousands of patients that no human, and no single test, could ever see on its own.
- Spot signatures that flag aggressive disease earlier.
- Predict who is likely to progress to castrate-resistant cancer — and when.
- Match each patient to the therapies and trials most likely to work for their biology.
- Track how a cancer is evolving in real time, between visits.
The result: insights that were simply not obtainable a few years ago — now within reach for the men and physicians who need them.
Oncovera is here to leverage the advances in omics and AI to obtain insights into prostate cancer that have never been obtainable before — and to translate them into better detection, better treatment, and better outcomes for every man on this journey.
Clarity, confidence, and precision at every stage.
We are building a new kind of prostate cancer company — one that helps transform care from a series of disconnected tests and decisions into a coordinated, personalized, and understandable experience.
About 1 in 8 men will be diagnosed with prostate cancer in his lifetime, and more than 333,000 new U.S. cases are expected in 2026. Yet prostate cancer is not one disease — it can be slow-moving, aggressive, recurrent, or treatable, often all at different moments.
Molecular diagnostics, imaging, clinical data, and advanced analytics that reveal the biology of each person’s cancer more clearly.
Helping patients and physicians navigate screening, diagnosis, recurrence, treatment, trials, and survivorship with more confidence.
A trusted place where men and families can feel informed, guided, and never alone through every step of the journey.
Science and empathy, brought together.
Prostate cancer care is filled with numbers — PSA, Gleason score, Grade Group, Decipher, PSMA, margins, staging, testosterone, ctDNA. Behind every number is a person trying to understand what it means for his life. The future of this care will not come from one test, one scan, or one algorithm — but from connecting the right information at the right time, and translating it into guidance people can actually use.
- You deserve answers that are understandable.
- You deserve care that sees the whole person, not just the tumor.
- You deserve a partner that can help you move from fear and confusion toward a plan.
Oncovera was created for that moment — when information becomes overwhelming, and guidance matters most.
We still lack the tools to make prostate cancer truly detectable, manageable, and monitorable.
Most of the tests men rely on today were not built for the questions we now need to answer.
PSA, for example, is prostate-specific, not cancer-specific. It can rise from cancer, but also from an enlarged prostate, inflammation, or simply age. It cannot tell us how aggressive a cancer is, where it is, or how it will behave next.
We need better ways to find aggressive cancer early — and to safely leave slow cancers alone — without putting every man through unnecessary biopsies.
Treatment decisions still rely on broad categories. We need tools that match each person to the therapy most likely to help them, with the fewest side effects.
We lack reliable ways to track progression to castrate-resistant disease, detect recurrence early, and see how a cancer is changing in real time — before it shows up on a scan.
Closing these gaps is why Oncovera exists. By bringing together molecular science, imaging, longitudinal data, and AI, we are building the tools that today's prostate cancer journey is missing — so that detection is sharper, decisions are clearer, and monitoring keeps pace with the disease.
Three Lines of Business. One Integrated Platform.
Oncovera Intelligence™
AI-powered platform transforming fragmented cancer information into longitudinal patient intelligence and decision support.
Explore →Oncovera Precision Sciences™
Advanced molecular diagnostics, computational biology, biomarker discovery, and translational research.
Explore →Oncovera Centers™
Hospitality-inspired model for cancer navigation, men's health, survivorship, education, and whole-person support.
Explore →Each line stands on its own. Together, they create a powerful network effect — connecting digital intelligence, deep biology, and human care.
Let's build the future of oncology together.
Oncovera is actively forming relationships across the cancer ecosystem. We work with organizations whose mission, science, technology, or reach can help advance more intelligent, more humane cancer care.
Academic & Research Institutions
Joint research programs, translational studies, data collaborations, and co-development of clinical and molecular intelligence tools.
Diagnostic & Molecular Companies
Integration partnerships across genomics, liquid biopsy, pathology, imaging, and multi-omic platforms to enrich the Oncovera intelligence layer.
Health Systems & Provider Networks
Clinical deployment, second-opinion pathways, tumor board augmentation, and longitudinal patient navigation programs.
Pharmaceutical & Clinical Trial Networks
Trial matching, real-world evidence generation, biomarker-driven cohorts, and patient identification across precision oncology programs.
Technology & AI Partners
Model collaboration, infrastructure integration, secure data exchange, and joint development of decision-support capabilities.
Advocacy & Patient Communities
Co-designed resources, education programs, and patient-centered initiatives that put lived experience at the center of innovation.
How partnerships begin
- 01IntroductionShare who you are, what you're working on, and where you see alignment with Oncovera's ecosystem.
- 02DiscoveryWe meet to explore scientific, clinical, and strategic fit, and to scope a focused initial collaboration.
- 03ActivationWe define scope, governance, and success metrics, then move into a structured pilot or formal partnership.
Partnership inquiries are reviewed by Oncovera's leadership team. Please share an overview of your organization, your area of focus, and the type of collaboration you envision. Formal partnership channels and contact details will be provided during initial discussions.
Cancer Generates Data. Patients Need Intelligence.
Cancer care produces enormous amounts of information: pathology, imaging, labs, genomics, treatment histories, notes, trials, literature, preferences, outcomes.
But most of this remains scattered across portals, PDFs, institutions, and specialties. Patients are left to carry their own records, repeat their own histories, and interpret complex medical information without a unified system to help them.
Physicians face a similar challenge — making increasingly personalized decisions in an environment where the volume of available information exceeds the capacity of any single person to process it manually.
The problem is no longer lack of data. The problem is lack of connected intelligence.
"The future of oncology will not be defined by who has the most data. It will be defined by who can turn data into understanding."
The Learning System For Precision Oncology.
What is happening in the disease over time?
Which trials or therapies should be considered?
What signals exist across similar patients?
What does the patient need to move forward?
What has shifted since the last assessment?
What is the next best informed step?
Your Prostate Journey, Made Clear.
Prostate cancer generates a lifetime of information — PSA tests, biopsies, MRIs, genomic panels, treatments, side effects, and decisions. Most of it lives in disconnected portals and PDFs.
Oncovera Intelligence™ brings every piece of your journey into one calm, comprehensive view — so you and your care team always see the whole picture.
Every PSA result over time, with velocity, doubling time, and what it means.
Gleason score, cores positive, perineural invasion, all in plain language.
MRI, PSMA-PET, bone scans — lesions tracked across studies.
Germline and tumor testing — BRCA, HRR, MSI, AR-V7, and what each unlocks.
Surgery, radiation, ADT, chemo, novel therapies — with response and side effects.
Personalized matches based on your stage, biology, and history.
Your PSA has dropped 62% since starting treatment. Your most recent MRI shows no new lesions, and your BRCA2 result opens the door to 3 targeted trials.
Your treatment is working — your PSA is at its lowest point since diagnosis and imaging is clean. Because you carry a BRCA2 variant, you may benefit from a PARP inhibitor if your disease progresses, and you qualify for several leading-edge trials nearby. Your care team has been notified.
Revealing The Biology Behind The Disease
The future of oncology will be defined not only by where cancer is found, but by what the cancer is doing.
Through advanced diagnostics, translational research, computational biology, liquid biopsy, spatial biology, and single-cell analytics, Precision Sciences uncovers patterns conventional systems may miss.
Integrating genomic, transcriptomic, proteomic, and spatial data.
Blood- and fluid-based approaches to detect and monitor cancer signals.
Where cells are, how they interact, what that means for behavior.
Studying cancer at cellular resolution to identify heterogeneity.
Signals to improve diagnosis, risk, and treatment selection.
Modeling tumor–immune interaction to expand visibility.
A Hospitality-Driven Model For Cancer Navigation And Survivorship
Cancer affects more than the tumor. It affects energy, strength, nutrition, identity, intimacy, confidence, family, work, and the ability to plan the future.
Oncovera Centers™ combine cancer navigation, men's health, survivorship, education, exercise oncology, nutrition, digital tools, and community programming in a premium, hospitality-inspired environment.
Records, options, appointments, next steps.
Prostate, sexual, metabolic, hormone, fitness.
Treatment to recovery, monitoring, life beyond.
Strength, mobility, conditioning, recovery.
Composition, resilience, inflammation, practice.
Talks, workshops, expert sessions, content.
Records, referrals, consultations, follow-up.
Patients and families learning together.
Because patients do not live inside a lab report. They live inside families, communities, bodies, hopes, fears, and futures.
From Fragmented Records To Precision Navigation.
Records, labs, imaging, pathology, molecular data.
AI structures the record into a longitudinal timeline.
Clinical and molecular signals are connected.
Relevant options, trials, and next steps are identified.
The system evolves through data, outcomes, and feedback.
Precision oncology should not be a single report. It should be a continuously learning journey.
A New Category Between Information And Care.
Traditional navigation helps patients move through the healthcare system. Precision Navigation™ helps patients move through the complexity of cancer itself.
It combines medical records, disease biology, molecular testing, clinical trials, patient preferences, emerging science, and expert context into a more intelligent framework for decision support.
The goal is not to replace physicians. The goal is to help patients and physicians arrive at better questions and better-informed decisions.
Beginning With Prostate Cancer. Built For Pan-Cancer Expansion.
Prostate cancer presents a unique combination of challenges: screening uncertainty, variable aggressiveness, complex treatment tradeoffs, surveillance vs. intervention, PSA monitoring limitations, biochemical recurrence, molecular testing opportunities, and long-term survivorship.
This makes it an ideal starting point for building a precision oncology intelligence platform. The same architecture extends across genitourinary, breast, colorectal, lung, and other solid tumors where longitudinal data and molecular interpretation matter.
Start focused. Build deeply. Expand intelligently.
Designed for everyone navigating cancer.
Patients & Families
Understand your disease journey, organize records, prepare better questions, explore relevant trials, and connect digital insight with real-world support.
Physicians & Care Teams
Structured timelines, summaries, and dashboards to review complex histories efficiently and identify relevant considerations for discussion.
Health Systems
White-label patient portals, precision oncology navigation, engagement, trial recruitment, survivorship, and population analytics.
Industry & Research
Responsible collaboration across diagnostics, therapeutics, trials, translational research, real-world evidence, and computational oncology.
The Oncovera Intelligence Flywheel.
Every patient journey contains valuable information. When organized responsibly, that information can improve navigation, discovery, research, and future care.
- 01Patients generate data.
- 02Data becomes structured intelligence.
- 03Intelligence supports better navigation.
- 04Navigation creates better questions and decisions.
- 05Outcomes create new learning.
- 06Learning improves the system.
The result is not simply a database. It is an evolving cancer intelligence network.
Built On Principles That Matter.
Clear, organized, understandable information.
Supports clinical judgment, never replaces it.
Beyond surface diagnosis into cellular behavior.
Cancer changes; systems must evolve.
Privacy, consent, transparency, and ethics.
If markets deserve real-time intelligence, so do patients.
Cancer is also dynamic. It evolves, branches, responds, resists, hides, and returns. Yet too often, decisions are made from static documents. Oncovera brings the intelligence model of modern decision systems into oncology — so that every data point serves the patient.
Designed To Support A New Era Of Oncology.
Built For Collaboration.
Precision oncology cannot be built by one organization alone. Oncovera collaborates across academic medical centers, researchers, diagnostic companies, technology partners, health systems, pharmaceutical companies, clinical trial networks, advocacy organizations, and patient communities.
How partnerships begin
A focused conversation to understand mutual goals, timelines, and scientific alignment.
We co-design a scoped, time-bound pilot with clear objectives and shared metrics.
Successful pilots expand into deeper integration, joint research, and long-term collaboration.
Oncovera LLC is registered in SAM.gov for federal contracting, research, and life sciences innovation opportunities.
These classifications reflect Oncovera's work across precision oncology research, cancer intelligence platform development, clinical data integration, and scientific/technical advisory support.